At the 44th annual meeting of the European Association for the Study of Diabetes, Sanfoi-aventis announced the results from two studies, GINGER and LACE.
It shows that the basal-bolus insulin regimen with LANTUS(R: 65.81, +0.64, +0.98%) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and rapid-acting APIDRA(R: 65.81, +0.64, +0.98%) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes.
Basal-bolus insulin regimens that combine once-daily LANTUS( as a basal insulin with rapid-acting APIDRA at mealtime closely mimic normal physiologic insulin secretion that occurs in people without diabetes.When compared to pre-mixed insulin regimens, the GINGER and LACE data demonstrate an efficacy advantage and, in the LACE study, a cost advantage for the basal-bolus approach.The GINGER and the LACE data demonstrate an efficacy advantage and, in the LACE study, a cost advantage for the basal-bolus approach.
The GINGER study showed that when compared to conventional therapy with pre-mixed insulin, intensified insulin therapy with LANTUS and results in superior glycemic control.
Additional study findings showed that mean number of concomitant oral diabetes agents were 0.86 versus 1.14. Additional details about the GINGER and LACE data are included in the study abstracts, available at EASD.org.
You will find the full information about LANTUS(R: 65.81, +0.64, +0.98%), APIDRA(R: 65.81, +0.64, +0.98%) and diabetes in the complete text of the Press Release on site.